toremifene

(redirected from Toremifene citrate)

toremifene

 [tor´ĕ-mĭ-fēn″]
an analogue of tamoxifen that acts as an estrogen antagonist; used as the citrate salt in palliative treatment of metastatic breast carcinoma, administered orally.

toremifene

Oncology An antiestrogen that may control certain CAs, ↓ recurrence. Cf Tamoxifen.

toremifene

An anti-oestrogen drug used to treat oestrogen-dependent breast cancers that have spread. Most breast cancers are oestrogen-dependent. A brand name is Fareston.
References in periodicals archive ?
According to GTx Inc, Fareston (toremifene citrate) 60mg tablets is a selective estrogen receptor modulator approved in the US for the treatment of metastatic breast cancer in postmenopausal women.
Eisai's unit Eisai China Inc will distribute the breast cancer drug Fareston (toremifene citrate) and Eldepryl (selegiline hydrochloride), for treatment of Parkinson's disease.
announced today that it has entered into a comprehensive marketing agreement with Orion Corporation (Espoo, Finland) concerning Orion's breast cancer drug Fareston(R) (toremifene citrate) and its Parkinson's disease treatment Eldepryl(R)(selegiline hydrochloride).
The effects on BMD of toremifene citrate, a new SERM, were tested in a 6-month, placebo-controlled dose-finding study with 46 men with prostate cancer receiving ADT.
Upcoming treatments, such as denosumab and toremifene citrate, have demonstrated promise in this setting.
Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer.
ORLANDO -- Toremifene citrate, a selective estrogen receptor modulator, increased bone mineral density and improved lipid levels in men receiving androgen deprivation therapy for advanced prostate cancer, investigators reported at a symposium on prostate cancer sponsored by the American Society of Clinical Oncology,
ORLANDO -- Toremifene citrate, a selective estrogen receptor modulator, increased bone mineral density and improved lipid levels in men receiving androgen-deprivation therapy for advanced prostate cancer, investigators reported at a symposium on prostate cancer sponsored by the American Society of Clinical Oncology.
(NASDAQ: GTXI}, Memphis, Tenn., the Men's Health Biotech Company, has announced the results of a lipid interim analysis of the pivotal Phase III ADT clinical trial evaluating oral, once daily ACAPODENE(R) (toremifene citrate) 80mg for the treatment of the multiple serious side effects of androgen deprivation therapy (ADT) in men with advanced prostate cancer.
GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of ADT for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN.
Recently a new drug called Fareston (toremifene citrate) has also been found to fight breast cancer successfully.
ORLANDO -- Toremifene citrate, an estrogen blocker approved for the treatment of advanced breast cancer, significantly reduced the incidence of prostate cancer in high-risk patients enrolled in a double-blind, randomized, phase IIb trial.